tradmap

CTNM Earnings Contineum Therapeutics, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$2 -$1 $0 $0 2023 2024 2025
EPS
Revenue (annual)
$0 $25M $50M 2023 2024 2025
Revenue
Net income (annual)
-$60M -$19M $23M $0 2023 2024 2025
Net income

Quarterly results

Diluted EPS (quarterly)
-$2 -$0 $1 $0 Q2 '23 Q3 '23 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q1 '26 Q2 '26
EPS
Revenue (quarterly)
$0 $1 $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Revenue
Net income (quarterly)
-$16M -$8M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income

Reported EPS history

1–11 of 11
Q2 20262026-06-30-0.792026-07-3010-Q
Q1 20262026-03-31-0.392026-05-0510-Q
FY 20252025-12-31-2.172026-03-0510-K
Q2 20262025-06-30-1.242026-07-3010-Q
Q1 20262025-03-31-0.622026-05-0510-Q
FY 20252024-12-31-2.182026-03-0510-K
Q3 20242024-09-30-1.612024-11-0610-Q
Q2 20242024-06-30-1.352024-08-1410-Q
FY 20242023-12-310.082025-03-0610-K
Q3 20242023-09-300.432024-11-0610-Q
Q2 20242023-06-300.742024-08-1410-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.